On this page
Chromosome 3
Mid-size metacentric chromosome - home of the Lynch-syndrome mismatch-repair gene MLH1 and the VHL tumour suppressor.
Schematic of chromosome 3 showing the short (p) and long (q) arms. Arm ratio per GRCh38 - banding schematic.
Available at Jeen Health
Clinical tests that include this
Overview
Chromosome 3 accounts for approximately 6.5 per cent of the total DNA in a human cell, making it one of the larger autosomes. Current genome annotations identify approximately 1,100 protein-coding genes, many of which coordinate critical cellular functions such as DNA repair, cell-cycle control, and signal transduction. Clinically, chromosome 3 is perhaps best known for harbouring MLH1 and VHL, two tumour-suppressor genes whose loss of function predisposes individuals to hereditary cancer syndromes. The chromosome's metacentric architecture means the centromere sits near the middle, dividing the structure into a short arm (designated 3p) and a long arm (3q) of roughly similar length. This balanced geometry helps ensure reliable segregation during cell division.
Beyond cancer predisposition, chromosome 3 carries genes implicated in metabolic enzyme deficiencies, cardiac electrophysiology disorders, and immune-system variation. Because the chromosome spans approximately 198 million base pairs, large deletions or duplications are comparatively uncommon in live births compared with smaller chromosomes. Whole-chromosome trisomy or monosomy of chromosome 3 is typically incompatible with embryonic survival, so clinical cytogenetics encounters of this chromosome more often involve submicroscopic deletions, balanced translocations, or single-gene pathogenic variants detected through targeted or exome sequencing.
Structure
Like all human chromosomes, chromosome 3 comprises a single molecule of double-stranded DNA wound around histone proteins to form nucleosomes, the repeating units of chromatin. During interphase, chromatin exists in a relatively relaxed state that permits transcription and DNA repair; as a cell prepares to divide, the chromatin condenses progressively until the chromosome adopts its familiar X-shaped metaphase configuration. The centromere of chromosome 3 lies near the midpoint, classifying it as metacentric. This central constriction is the attachment site for spindle microtubules during mitosis and meiosis, and its repetitive DNA sequences are essential for accurate chromosome movement. The short arm (3p) and long arm (3q) each contain distinct cytogenetic bands visible under the microscope after staining, and these bands serve as address labels for mapping genes and structural variants.
Each end of the chromosome terminates in a telomere, a protective cap of repetitive sequences that safeguards coding DNA from degradation during successive rounds of replication. Over a person's lifetime, telomeres shorten with each cell division, eventually triggering senescence or programmed cell death. Chromosome 3 does not belong to the acrocentric group, so it lacks the ribosomal-RNA gene clusters found on the short arms of chromosomes 13, 14, 15, 21, and 22. Instead, both arms of chromosome 3 contain a mix of gene-rich and gene-poor regions, with variations in guanine-cytosine content influencing local chromatin accessibility and expression levels.
Video: What is a karyotype?
Notable regions
The 3p22.2 band is home to MLH1, one of the best-characterised mismatch-repair genes in the human genome. Pathogenic variants in MLH1 account for a substantial proportion of Lynch syndrome cases, a condition marked by elevated risks of colorectal, endometrial, and other cancers from early adulthood. The MLH1 protein partners with other mismatch-repair factors to scan newly replicated DNA for base-pairing errors, excising mismatched nucleotides and recruiting polymerases to fill the gaps accurately. When both copies of MLH1 carry damaging variants (either through germline inheritance plus a somatic second hit, or through biallelic germline inheritance), cells accumulate replication errors at an accelerated rate, fuelling tumourigenesis. The same band also hosts SCN5A, which encodes the main cardiac sodium channel and is implicated in a spectrum of arrhythmia disorders including Brugada syndrome, long QT syndrome type 3, and progressive cardiac conduction defect.
Further toward the tip of the short arm at 3p25.3 lies VHL, the von Hippel-Lindau tumour suppressor. The VHL protein regulates how cells respond to hypoxia by targeting a transcription factor for degradation when oxygen is plentiful. Loss of VHL function leads to inappropriate stabilisation of that transcription factor even in normoxic conditions, driving the formation of highly vascular tumours in the retina, cerebellum, spinal cord, kidneys, and adrenal glands. Germline pathogenic variants in VHL cause von Hippel-Lindau syndrome, an autosomal dominant cancer predisposition condition managed through lifelong surveillance imaging and early intervention.
The 3p21.31 region contains a cluster of chemokine-receptor genes, including CCR5, which has attracted attention in HIV research. A naturally occurring 32-base-pair deletion in CCR5 confers resistance to certain strains of HIV by disrupting the receptor's structure, preventing viral entry into immune cells. The same cytogenetic neighbourhood includes CACNA2D2, a calcium-channel auxiliary subunit linked to neurodevelopmental phenotypes, and MYL3, a myosin light chain critical for cardiac muscle contraction. The clustering of functionally diverse genes in 3p21.31 illustrates how evolutionary processes have shaped the local genomic architecture.
On the long arm, the 3q26.32 band harbours PIK3CA, a gene that encodes the catalytic subunit of phosphoinositide 3-kinase. Somatic variants in PIK3CA are among the most frequent alterations in human cancers, but germline mosaic variants also cause overgrowth syndromes such as CLOVES syndrome, Klippel-Trenaunay syndrome, and megalencephaly-capillary malformation syndrome. The distribution of these mosaic variants across different tissues determines the clinical presentation, with some individuals experiencing isolated limb overgrowth and others displaying widespread vascular malformations. At 3p24.1, TGFBR2 encodes transforming growth factor-beta receptor type 2, a cell-surface receptor whose disruption is associated with familial thoracic aortic aneurysm and Loeys-Dietz syndrome.
Notable genes
MLH1 stands out as one of the most clinically consequential genes on chromosome 3. As a DNA mismatch-repair gene, MLH1 coordinates the correction of base-pairing mistakes that escape proofreading during DNA replication. Individuals who inherit one pathogenic MLH1 variant have Lynch syndrome and face substantially elevated lifetime risks of colorectal and endometrial cancer, typically with onset in the fourth or fifth decade (age 30-50). When both alleles carry damaging changes from birth, the result is constitutional mismatch-repair deficiency, a rare childhood cancer predisposition syndrome characterised by very early onset brain tumours, leukaemias, and gastrointestinal malignancies. UK guidelines recommend colonoscopic surveillance from young adulthood for Lynch syndrome families, with some centres offering annual or biennial screening depending on individual risk.
VHL encodes a protein central to cellular oxygen sensing. Under normal oxygen conditions, VHL tags a transcription factor called hypoxia-inducible factor for destruction; when oxygen levels drop, VHL releases its grip, allowing the cell to switch on genes that promote blood-vessel formation and metabolic adaptation. Germline pathogenic variants in VHL lead to constitutive activation of hypoxia pathways, triggering the growth of haemangioblastomas in the central nervous system and retina, clear-cell renal carcinomas, and phaeochromocytomas. Surveillance protocols for von Hippel-Lindau syndrome typically include regular retinal examination, brain and spinal MRI, and abdominal imaging to detect tumours early. BAP1, located at 3p21.1, encodes a deubiquitinase involved in chromatin remodelling and DNA-damage response. Pathogenic variants in BAP1 predispose individuals to uveal melanoma, malignant mesothelioma, renal cell carcinoma, and a distinctive type of skin lesion, illustrating how a single gene can influence cancer risk across multiple tissue types.
Chromosomal disorders
Whole-chromosome aneuploidy involving chromosome 3 (trisomy 3 or monosomy 3) is typically lethal during early embryonic development and is rarely seen in live births. Post-implantation lethality reflects the dosage imbalance of more than a thousand genes, many of which are essential for cell survival and tissue differentiation. As a result, clinical genetics services in the UK do not routinely encounter constitutional trisomy 3 in the postnatal setting, although confined placental mosaicism for trisomy 3 is occasionally detected during prenatal diagnosis and may be associated with intrauterine growth restriction.
Submicroscopic deletions and duplications affecting specific regions of chromosome 3 are more compatible with survival but can cause recognisable developmental syndromes. For example, deletions encompassing 3p that include VHL and other nearby genes may present with intellectual disability, growth delay, and an increased risk of renal tumours. The clinical phenotype depends on the size and gene content of the deletion, and chromosomal microarray analysis is the first-tier test for unexplained developmental delay or multiple congenital anomalies. Duplications of segments of chromosome 3 are less common but have been reported in individuals with neurodevelopmental phenotypes. Because chromosome 3 does not harbour known imprinted regions, uniparental disomy (inheriting both copies from one parent) is not typically associated with a distinct clinical syndrome, unlike chromosomes 7, 11, 14, and 15.
Balanced translocations involving chromosome 3 may come to clinical attention through a family history of recurrent miscarriage or the birth of a child with an unbalanced karyotype. Carriers of balanced rearrangements are usually phenotypically normal, but their offspring can inherit an unbalanced complement of genetic material, leading to developmental disorders. NHS regional genetics laboratories offer karyotyping and, where indicated, microarray or breakpoint sequencing to characterise these rearrangements and inform reproductive counselling.
Prenatal screening & diagnosis
Non-invasive prenatal testing, which analyses cell-free foetal DNA circulating in maternal blood, is primarily validated for the common autosomal trisomies (chromosomes 13, 18, and 21) and does not routinely screen for whole-chromosome abnormalities of chromosome 3; some extended panels may detect large deletions or duplications. Because whole-chromosome trisomy 3 is embryonically lethal, it would not be detected in ongoing pregnancies. If a structural anomaly is identified on routine antenatal ultrasound and there is suspicion of a genetic cause, the NHS Fetal Anomaly Screening Programme pathway may lead to an offer of invasive testing (amniocentesis or chorionic villus sampling) followed by karyotyping or chromosomal microarray to exclude large deletions or duplications.
When a familial balanced translocation involving chromosome 3 is known, preimplantation genetic testing or invasive prenatal diagnosis with targeted analysis can clarify whether a fetus has inherited a balanced or unbalanced arrangement. Pregnant women with a personal or family history of Lynch syndrome or von Hippel-Lindau syndrome may be offered genetic counselling; however, because these are autosomal dominant conditions with postnatal onset, prenatal testing is not routinely performed unless specifically requested. NHS clinical genetics services emphasise informed choice, ensuring families understand the implications of testing and the availability of surveillance and early intervention for at-risk individuals after birth.
Inheritance & recurrence
The majority of clinically significant chromosome 3 abnormalities encountered in NHS genetics clinics are either de novo (arising as new events in the affected individual) or inherited in an autosomal dominant pattern. For single-gene disorders such as Lynch syndrome and von Hippel-Lindau syndrome, each child of an affected parent has a 50 per cent chance of inheriting the pathogenic variant. Penetrance varies by gene and variant type: many MLH1 pathogenic variants confer high lifetime cancer risks, whereas some VHL variants show incomplete penetrance or variable expressivity, meaning not all carriers develop the full spectrum of tumours.
De novo deletions or duplications involving chromosome 3 typically carry low recurrence risks for future siblings, barring parental germline mosaicism. If microarray analysis in a child identifies a copy-number variant on chromosome 3, parental samples are usually tested to determine whether the variant is inherited or de novo; an inherited variant may prompt cascade testing in the extended family, whereas a de novo change generally implies a recurrence risk close to the population baseline. Families are referred to clinical genetics for personalised recurrence-risk counselling, particularly when planning further pregnancies.
For autosomal recessive conditions such as biotinidase deficiency (caused by pathogenic variants in BTD at 3p25.1), both parents are typically carriers, and each pregnancy carries a 25 per cent risk of an affected child. The NHS Newborn Blood Spot Screening Programme does not currently screen for biotinidase deficiency in the UK, so diagnosis usually occurs after clinical presentation or through targeted testing when there is a family history. Carrier screening is available for at-risk relatives, and reproductive options including preimplantation genetic testing can be discussed with a genetics specialist.
Frequently asked questions
If I carry a pathogenic variant in MLH1 on chromosome 3, will I definitely develop cancer?
Carrying a pathogenic MLH1 variant substantially increases your lifetime risk of colorectal, endometrial, and other cancers, but it does not guarantee that cancer will develop. Many people with Lynch syndrome benefit from regular colonoscopic surveillance, which can detect and remove precancerous polyps before they progress. Your NHS clinical genetics team can discuss personalised risk estimates and screening options.
Can chromosome 3 abnormalities be detected during pregnancy?
Non-invasive prenatal testing does not routinely screen for chromosome 3 abnormalities, because whole-chromosome trisomy 3 is not compatible with survival to term. If an ultrasound finding raises concern for a genetic condition, invasive testing with karyotype or microarray can identify deletions, duplications, or translocations involving chromosome 3. Your midwife or obstetrician can refer you to foetal medicine for counselling if needed.
How common are conditions caused by chromosome 3 genes?
Lynch syndrome, caused by variants in MLH1 and other mismatch-repair genes, is estimated to affect around one in 300 to one in 400 people in the UK, making it one of the more common inherited cancer syndromes. Von Hippel-Lindau syndrome is rarer, with an estimated prevalence of around one in 36,000. Other conditions linked to chromosome 3 genes, such as Brugada syndrome or BAP1 tumour predisposition syndrome, are less common but collectively contribute to a significant burden of inherited disease.
What is the difference between a deletion of chromosome 3 and a pathogenic variant in a gene on chromosome 3?
A deletion removes a segment of the chromosome and can affect multiple genes at once, often leading to developmental delay or intellectual disability alongside other features. A pathogenic variant is a change within a single gene that disrupts its normal function. Both can be detected through genetic testing, but deletions are usually identified by chromosomal microarray, whereas single-gene variants are found through targeted gene panels or exome sequencing.
If my child has a de novo deletion on chromosome 3, what is the chance it will happen again in a future pregnancy?
When a deletion arises as a new event (de novo) in your child, the recurrence risk for future pregnancies is generally low, typically quoted at around one to two per cent to account for the small possibility of parental germline mosaicism. Your clinical genetics team can provide a more precise estimate based on your family history and whether either parent carries the deletion in a low-level mosaic form.
Launch-set genes on chromosome 3
Genes on this chromosome that currently have dedicated pages in the library. This list grows as we publish more.